DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Information source: Galectin Therapeutics Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colorectal Cancer

Intervention: GM-CT-01 plus 5-Fluorouracil (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Galectin Therapeutics Inc.


This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon cancer which has spread, despite treatment with approved therapies, will receive GM-CT-01 plus 5-FU in monthly cycles for at least 2 cycles or until their disease progresses.

Clinical Details

Official title: A Phase II, Multi-Center, Open-Label Trial to Evaluate the Efficacy and Safety of Intravenous GM-CT-01 in Combination With 5-Fluorouracil When Administered in Monthly Cycles as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

frequency of objective complete or partial tumor response

frequency of stable disease

Secondary outcome: safety of GM-CT-01 plus 5-FU

Detailed description: A Phase I study of 40 patients showed that GM-CT-01 in different doses plus 5-FU was well tolerated in patients with different types of solid tumors who failed standard, approved treatments. The main reason for doing this Phase II study in advanced colorectal cancer patients is to verify the safety observations in the early Phase I study and further evaluate the efficacy of these drugs' combination to stabilize tumors, preventing further growth and potentially shrink tumors.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- 18 years of age or older

- Has a histologically-proven adenocarcinoma of the colon or rectum

- Has documentation of locally advanced or metastatic colorectal cancer not amenable to

curative surgery or radiotherapy

- Eligible subjects are those whose unresectable, locally advanced and/or metastatic

colorectal cancer has progressed during or after receiving treatment with at least two, but not more than three, lines of therapy that collectively must have included at a minimum all of the following agents: 5-fluorouracil or capecitabine, irinotecan, and oxaliplatin (unless, in the opinion of the investigator, the subject is not able to receive irinotecan and/or oxaliplatin due to medical contraindications, in which case irinotecan and/or oxaliplatin are not required to have been included in the prior lines of therapy). Adjuvant chemotherapy following definitive management of the primary lesion in the colon or rectum is allowed and will not be counted as a line of therapy.

- Has 1 or more measurable lesion(s) ("target lesion[s]") according to RECIST (Response

Evaluation Criteria in Solid Tumors) criteria. The same diagnostic imaging method must be used throughout the study to evaluate the lesions; and clinically detected lesions will only be considered measurable when they are superficial (e. g., skin nodules and palpable lymph nodes).

- Has an ECOG performance status of 0-2

- Has a life expectancy greater than 3 months

- Has the ability to understand the nature of the study and any hazards of

participating in it; to communicate satisfactorily with the Investigator; and to participate in, and comply with, the requirements of the entire study

- A female of childbearing potential must have a negative serum screening test for

pregnancy and agree to practice abstinence or use an effective method of contraception

- Has had all aspects of the protocol explained and written informed consent obtained

Exclusion Criteria:

- Has central nervous system metastasis

- Has bony metastasis as the sole metastasis

- Has other concomitant or previous malignancy in the past 3 years, except:

- adequately treated in situ carcinoma of the uterine cervix;

- basal or squamous cell carcinoma of the skin; and/or

- melanoma in situ.

- Is receiving concomitant anti-neoplastic treatment; has received radiation therapy in

the past 3 weeks; has been treated with anti-angiogenesis agents, including bevacizumab, in the past 4 weeks; or has been treated with any other chemotherapeutic agents in the past 4 weeks (6 weeks for mitomycin C and nitrosoureas).

- Has an active infection

- Has congestive heart failure (Class III or IV in the New York Heart Association

functional classification system)

- Has a hemoglobin level of < 8. 5 gm/dL

- Has a platelet count of < 100,000/mm3

- Has a neutrophil count of < 1,500/mm3

- Has a serum creatinine level of > 2. 0 mg/dL

- Has liver aminotransferase and alkaline phosphatase levels that are > 2. 5 times the

laboratory's upper limit of normal (ULN) in a subject with no liver metastases, and levels that are > 5 times the laboratory's ULN in a subject with liver metastases

- Has a total bilirubin level that is > 2 times the laboratory's ULN

- Has pulmonary DLCO < 60% of predicted

- Has known or clinically suspected infection with human immunodeficiency virus (HIV)

- Has participated within 30 days, or will participate concurrently, in another

investigational drug or vaccine study

- Has a history of drug or alcohol dependence in the past 3 years

- Has other serious, non-malignant, significant, acute or chronic medical or

psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study

- Has known intolerance to 5- FU

- Has previously participated in a GM-CT-01 clinical trial

- Has known hypersensitivity to GM-CT-01 or any of its components

Locations and Contacts

Soroka University Medical Center, Beer-Sheva 84101, Israel

Shaare Zedek Medical Center, Oncology, Jerusalem 91031, Israel

Medical Oncology and Hematology, Waterbury, Connecticut 06708, United States

Hematology-Oncology Associates of the Treasure Coast, Port St. Lucie, Florida 34952, United States

Ochsner Clinic Foundation, New Orleans, Louisiana 70121, United States

University of Michigan Comprehensive Cancer Center, Ann Arbor,, Michigan, United States

Additional Information

Sponsor's website

Starting date: May 2005
Last updated: March 5, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017